{"id":4306,"date":"2026-11-13T09:00:00","date_gmt":"2026-11-13T13:00:00","guid":{"rendered":"https:\/\/www.insilens.com\/?p=4306"},"modified":"2026-11-14T12:48:23","modified_gmt":"2026-11-14T16:48:23","slug":"clec9a-and-dec205-car-dendritic-cells","status":"publish","type":"post","link":"https:\/\/www.insilens.com\/?p=4306","title":{"rendered":"CLEC9A and DEC205 CAR Dendritic Cells"},"content":{"rendered":"<p><img fetchpriority=\"high\" decoding=\"async\" width=\"768\" height=\"432\" src=\"https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261113_Suzhou_Institute_Technology_and_Modalities-768x432.png\" alt=\"\" class=\"attachment-medium_large size-medium_large wp-image-4311\" srcset=\"https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261113_Suzhou_Institute_Technology_and_Modalities-768x432.png 768w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261113_Suzhou_Institute_Technology_and_Modalities-300x169.png 300w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261113_Suzhou_Institute_Technology_and_Modalities-1024x576.png 1024w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261113_Suzhou_Institute_Technology_and_Modalities-1536x864.png 1536w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261113_Suzhou_Institute_Technology_and_Modalities.png 1672w\" sizes=\"(max-width: 768px) 100vw, 768px\" \/><\/p>\n<p><strong>Company<\/strong><\/p>\n<p>Suzhou Institute of Systems Medicine (academic)<\/p>\n<p><strong>Event Type<\/strong><\/p>\n<p>Peer-reviewed publication (Nature Immunology)<\/p>\n<p><strong>Modality<\/strong><\/p>\n<p>CAR-engineered dendritic cells<\/p>\n<p><strong>Asset<\/strong><\/p>\n<p>CLEC9A\/DEC205 CAR-DC<\/p>\n<p><strong>Target<\/strong><\/p>\n<p>Tumor antigens (CAR); CLEC9A; DEC205 signaling<\/p>\n<p><strong>Disease Area<\/strong><\/p>\n<p>Solid tumors (preclinical models)<\/p>\n<h4>Summary<\/h4>\n<p>A Nature Immunology paper published online November 13 describes engineered dendritic cells whose CAR intracellular domains borrow from the endocytic receptors CLEC9A or DEC205. The preclinical work links antigen uptake and cross-presentation to tumor-reactive CD8 T-cell responses in mouse and humanized models.<\/p>\n<p>The peer-reviewed article follows a February 2026 Research Square preprint from the Suzhou Institute of Systems Medicine and collaborators. Its reported mechanism includes SYK-associated signaling, enhanced antigen processing and T-cell priming. The author team reports tumor-growth suppression in murine and humanized models. The earlier preprint discloses an institute patent application covering CAR-DC preparation and function; the published article, rather than the preprint, is the new evidence class in this window.<\/p>\n<h4>Deep Analysis<\/h4>\n<p>Mechanistic novelty is the substitution of endocytic-receptor intracellular machinery for a conventional T-cell-like CAR signaling program, potentially converting tumor encounter into antigen presentation rather than direct cytotoxicity. <strong>Interpretation A:<\/strong> CAR-DCs could amplify endogenous polyclonal T-cell immunity and address antigen heterogeneity in solid tumors; cross-presentation and humanized-model activity support this.<\/p>\n<p><strong>Interpretation B:<\/strong> controlled model systems overstate clinical durability because tumor access, DC maturation, immunosuppressive microenvironments and product variability may dominate in patients. No human efficacy, persistence, dose, biodistribution, repeat-dosing safety or scalable GMP manufacturing evidence was identified. Cytokine activation, off-tumor antigen capture and allogeneic compatibility require investigation. Patent filing establishes a claimed position, not freedom to operate.<\/p>\n<h4>Company and Product Background<\/h4>\n<p>Dendritic cells process and present antigens to na\u00efve and memory T cells. CLEC9A and DEC205 are endocytic receptors associated with antigen routing. The engineered CAR-DC concept aims to recruit a patient\u2019s endogenous T-cell repertoire against solid tumors; no specific approved product or disease indication is established.<\/p>\n<h4>Signal Extraction<\/h4>\n<ul>\n<li>Signal: a programmable immune-cell architecture with potential platform value.<\/li>\n<li>Missing: human clinical data, comparative potency against existing DC vaccines or CAR macrophages, PK and persistence, and cost-of-goods.<\/li>\n<li>Upgrade: replicated human tumor-slice activity, defined manufacturing release criteria and an IND-enabling safety package.<\/li>\n<li>Downgrade or falsify: absent cross-presentation in human tumors or unacceptable inflammatory toxicity at active doses.<\/li>\n<\/ul>\n<h4>InSilens Take<\/h4>\n<p>This is a credible preclinical modality signal, not a treatment-ready CAR cell product. Peer review increases confidence in the reported experiments; translation remains uncertain.<\/p>\n<h4>Signal Assessment<\/h4>\n<p>Signal Importance: 4 of 5. Signal Direction: uncertain. Confidence in Facts: moderate to high for publication and described preclinical results. Confidence in Interpretation: low to moderate for clinical transfer.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>A Nature Immunology paper published online November 13 describes engineered dendritic cells whose CAR intracellular domains borrow from the endocytic receptors CLEC9A or DEC205. The preclinical work links antigen uptake and cross-presentation to tumor-reactive&#8230;<\/p>\n","protected":false},"author":1,"featured_media":4311,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4],"tags":[1492,1493,1491],"class_list":["post-4306","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-technology-modalities","tag-car-dendritic-cells","tag-nature-immunology","tag-suzhou-institute-of-systems-medicine"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4306","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=4306"}],"version-history":[{"count":1,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4306\/revisions"}],"predecessor-version":[{"id":4331,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4306\/revisions\/4331"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/4311"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=4306"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=4306"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=4306"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}